Soluble CD146, a novel endothelial marker, is increased in physiopathological settings linked to endothelial junctional alteration
Abstract number: P1739
Bardin* N., Anfosso F., Daniel L., Moal V., Brunet P., Sampol J., Dignat George F.
*INSERM EMI0019 Université de la Méditerranée, France; PhD, France
CD146, a novel cell adhesion molecule localized at the endothelial junction, is involved in the control of cell-cell cohesion. It is found as a soluble form in conditioned medium of cultured endothelial cells. We developed an ELISA and report for the first time the presence of a soluble form of CD146 (sCD146) in the plasma of healthy subjects. Mean sCD146 values (221.4 ± 142.2 ng mL-1) were not influenced by sex but were increased by age. We therefore investigated sCD146 values in patients with chronic renal failure (CRF), a clinical setting associated with permeability alterations. A significant increase in sCD146 was found in patients with CRF matched with controls (553.1 ± 186.2 ng mL-1 vs. 337 ± 53.59 ng mL-1, respectively, P < 0.0001). This increase was corroborated by increased endothelial expression of CD146 on kidney biopsies from patients with CRF. In contrast, in patients with CRF no modulation was observed for the soluble and cell-associated form of CD31, another junctional molecule. Together these data indicate that sCD146 circulates in the plasma of healthy subjects. Modifications of its basal levels could potentially reflect alterations of junctional functions such as vascular permeability.
To cite this abstract use the following format:
Journal of Thrombosis and Haemostasis 2003; 1 Supplement 1 July: abstract number
|Back to top|